Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine extension study for diabetic peripheral neuropathic pain
NCT00641719Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of duloxetine in diabetic polyneuropathy (DPN) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Who Experienced an Adverse Event at 1 year. Started Mar 2008; status: completed.
02
Drugs
duloxetine
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT00641719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00641719.